Targeting PIM kinase activity significantly augments the efficacy of cytarabine
Kevin R. Kelly(Keck Hospital of USC), Jennifer S. Carew(University of Arizona), Pietro Taverna, Claudia M. Espitia(The University of Texas System), Gavin Choy(SuperGen (United States)), Francis J. Giles(National University of Ireland), Steffan T. Nawrocki(University of Arizona)
Cited by 22
Related Papers
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782